Vortioxetine Manufacturer 508233-74-7 For Antidepressants CAS NO.508233-74-7

Min.Order Quantity:: 10 Gram

Purity:: 99%

Port:: Wuhan

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

99%min Vortioxetine
Vortioxetine Manufacturer
For Antidepressants

Quick Details

ProName: Vortioxetine Manufacturer 508233-74-7 ...
CasNo: 508233-74-7
Molecular Formula: C18H22N2S
Appearance: White Powder
Application: It Can Be Used As Pharmaceutical Inte...
DeliveryTime: 2-4 days after confirming your payment...
PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
Port: Wuhan
ProductionCapacity: 10000 Metric Ton/Month
Purity: 99%
Storage: Store in sealed containers at cool & d...
Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
LimitNum: 10 Gram

Superiority

advantages:

hubei xinrunde chemical co., ltd is a renowned pharmaceutical manufacturer. we can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. never stop striving to offer our best service is our philosophy. we have flexible and untraceable payment terms. as a leading manufacture, our products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries.

1. quality.every batch of steroid powders have tobetested by our qc(quality control) before they are allowed to sell.

2. delivery we have stock, so we can delivery quickly at the very day when receive the payment. within 24 hours after receiving the payment lead time 4 or 7 days.

3. discreet package safelyand professionally disguised package guaranteed. for your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. warm after-sale service any of your question would be solved for the first as soon as possible.

Details

vortioxetine basic information

curative for major depression disorder mechanism of action pharmacokinetics drug interaction synthesis

product name:	vortioxetine
synonyms:	trintellix (vortioxetine);vortioxetine(lu aa21004);1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine-hcl;vortioxetin;vortioxetine, >=99%;1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine;lu aa 21004;vortioxetine
cas:	508233-74-7
mf:	c18h22n2s
mw:	298.44568
einecs:	1308068-626-2
product categories:	inhibitors;5-ht antagonist;serotonin transporter inhibitor
mol file:	508233-74-7.mol

vortioxetine chemical properties

density

1.16

vortioxetine usage and synthesis

curative for major depression disorder	vortioxetine is a new drug for treating depression, jointly developed and researched by the danish lundbeck (lundbeck) and japanese takeda. in september 30, 2013, it is approved by the u.s. food and drug administration (fda) to enter into market with the brand name of brintellix, for major depression disorder (mdd) treatment. in october 2013, the european medicines agency (ema)’s subordinate agency: committee for medicinal products for human use (chmp) recommended that vortioxetine for the treatment of severe depression should be licensed in the european market and be launched into the european market in january 2014. mdd features mood changes and a series of other symptoms, which have a great impact on the patient's ability to work, sleep, study, eat and enjoy the current happiness. depressive symptoms can recur many times in life, but some patients may experience only once. vortioxetine, mainly by increasing the concentration of serotonin (5-ht) in the central nervous system (cns), exerts antidepressant effects. compared with other selective serotonin reuptake inhibitors (ssris) or serotonin-norepinephrine reuptake inhibitors (snris), vortioxetine almost has no effect on norepinephrine and dopamine neurons. a number of clinical trials have demonstrated the efficacy, safety and tolerability of vortioxetine in the treatment of mdd. figure 1 shows the structure of vortioxetine.
mechanism of action	vortioxetine is a small molecule piperazine sulfide. who w classifies it as antidepressants (n06a). the drug classification system of european pharmaceutical market research association (ephmra) classifies it as hypnotic / sedative drugs (n5b), antidepressants and mood stabilizers (n6a). currently, depression is thought to be associated with a decrease in 5-ht activity, and decreased activity of norepinephrine (ne) and dopamine (da) is thought to be associated with depression. vortioxetine is a potent serotonin reuptake inhibitor. in human body it has high affinity with serotonin trans-porter (ki=1.6 nmol - l - 1). but it almost has no affinity with norepinephrine transporter (ki=113nmol - l-1) and dopamine transporter (ki= 1000nmol - l - 1). at the same time, it is also a 5-ht1a receptor agonist and 5-ht1b receptor partial agonist, 5-ht1d, 5-ht3 and 5-ht7 receptor antagonist and 5-ht uptake inhibitor. animal studies have shown that in rats, vinpocetine through interaction on these receptors, will increase depression related brain regions -- the level of the ventral hippocampus, prefrontal cortex extracellular serotonin , dopamine, norepinephrine, acetylcholine and histamine, at the same time it is also regulating the function of y -gaba (γ-aminobutyric acid) and glutamatergic neuron, thus exerting the effect of antidepressant.
pharmacokinetics	the relative molecular weight of vortioxetine is small, and the plasma protein binding rate is 98 percent, which is not related to plasma concentration. it is widely distributed outside the cell and the apparent distribution volume is about 2600 l. daily oral administration is 2.5 ~ 60mg, showing the linear pharmacokinetic characteristics in proportion to dosage of administration. bioavailability is 75 percent and generally after 2 weeks of taking vortioxetine, its concentration will be stable in blood. cmax is 7 to 11 hours. vortioxetine is metabolized mainly by oxidation and glucuronidation . after a single oral administration of the radioisotope labeled vortioxetine, about 59 percent of it is excreted through the urine, and about 26 percent were excreted through the feces. there was almost no original vortioxetine 48 hours after administration of the drug. the complete metabolism in body requires about 66 hours. the oxidation is mainly completed through cytochrome p450 enzyme (cyp). the involved cyp includes cyp3a4/5, cyp2c19, cyp2c9, cyp2a6, cyp2c8, cyp2b6 and cyp2d6. among them, cyp2d6 is the key enzyme which catalyzes and produces the main metabolite of duloxetine carboxylic acid. the drug concentration of cyp2d6 in the plasma with slow metabolism is twice higher than that of cyp2d6 in the plasma with the fast metabolism.
drug interaction	in the different experiment and researches using healthy volunteers as subjects, vortioxetine will be co-administered respectively with cyp2d6 inhibitor bupropion, cyp2c9/cyp2c19/cyp3a inhibitor fluconazole or cyp3a/ permeability glycoprotein (p-gp) inhibitor ketoconazole. the vortioxetine’s bioavailability will increase. therefore when vortioxetine and strong cyp2d6 inhibitors (such as bupropion, fluoxetine, paroxetine and quinidine) are co-administered, the dosage should be halved. when vortioxetine and strong cyp inducers (rifampicin) are co-administered, its bioavailability will be reduced. therefore when vortioxetine is co-administered with rifampicin or other strong cyp inducers (such as carbamazepine, phenytoin sodium), the dosage should be increased, but the maximum dosage should not be three times higher than the normal dose. in addition, the use of 5-ht drugs itself is a risk factors of incurring abnormal bleeding. therefore when vortioxetine is co-administered with aspirin, nonsteroidal anti-inflammatory drugs or other drugs affecting blood coagulation, special attention should be drawn to the abnormal bleeding of patients. considering the functional mechanism of vortioxetine and potential toxicity of serotonin, so when it is co-administered with other drugs affecting 5-ht neurotransmitter systems (such as ssris, snris, and triptans, buspirone, tramadol and tryptophan products), lt is likely to occur 5-ht syndrome. therefore, close attention should be paid to the risk of 5-ht syndrome when it is used in combination with such drug. once the 5-ht syndrome occurs, all such drugs should be discontinued immediately. similar to the above reasons, monoamine oxidase inhibitors (maois) are prohibited from being used in combination with maois. maois can not be administered within 21d after discontinuation of vortioxetine, and vortioxetine can not be administered within 14d after discontinuation of maois. because the combination of both will increase the risk of 5-ht syndrome in patients.